| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 151 | 2025 | 763 | 22.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 21 | 2025 | 489 | 6.750 |
Why?
|
| Indans | 29 | 2017 | 53 | 4.570 |
Why?
|
| Cholinesterase Inhibitors | 29 | 2017 | 90 | 4.470 |
Why?
|
| Cognition Disorders | 28 | 2016 | 555 | 4.200 |
Why?
|
| Piperidines | 29 | 2017 | 200 | 4.180 |
Why?
|
| Amyloid beta-Peptides | 21 | 2025 | 205 | 4.090 |
Why?
|
| Neuropsychological Tests | 56 | 2021 | 925 | 3.330 |
Why?
|
| Cognition | 30 | 2022 | 738 | 3.030 |
Why?
|
| Activities of Daily Living | 24 | 2021 | 404 | 2.940 |
Why?
|
| Nootropic Agents | 18 | 2017 | 25 | 2.680 |
Why?
|
| Dementia | 27 | 2016 | 448 | 2.410 |
Why?
|
| Aged, 80 and over | 78 | 2025 | 6374 | 2.230 |
Why?
|
| Aged | 134 | 2025 | 19101 | 2.130 |
Why?
|
| Clinical Trials as Topic | 24 | 2024 | 1080 | 2.120 |
Why?
|
| Cognitive Dysfunction | 7 | 2023 | 225 | 2.080 |
Why?
|
| Double-Blind Method | 33 | 2025 | 1583 | 1.920 |
Why?
|
| Memantine | 9 | 2012 | 17 | 1.830 |
Why?
|
| Psychiatric Status Rating Scales | 25 | 2016 | 805 | 1.680 |
Why?
|
| Disease Progression | 31 | 2024 | 2028 | 1.680 |
Why?
|
| Drug Approval | 2 | 2023 | 40 | 1.540 |
Why?
|
| Mental Status and Dementia Tests | 6 | 2023 | 17 | 1.330 |
Why?
|
| Excitatory Amino Acid Antagonists | 6 | 2016 | 96 | 1.320 |
Why?
|
| Brain | 18 | 2025 | 2967 | 1.300 |
Why?
|
| Severity of Illness Index | 30 | 2021 | 2847 | 1.250 |
Why?
|
| Humans | 188 | 2025 | 123120 | 1.230 |
Why?
|
| Male | 121 | 2025 | 60140 | 1.210 |
Why?
|
| Middle Aged | 84 | 2025 | 26002 | 1.170 |
Why?
|
| Psychometrics | 14 | 2021 | 665 | 1.150 |
Why?
|
| Female | 123 | 2025 | 65527 | 1.130 |
Why?
|
| Plaque, Amyloid | 4 | 2022 | 63 | 1.080 |
Why?
|
| Feasibility Studies | 2 | 2024 | 756 | 1.020 |
Why?
|
| Amnesia | 4 | 2011 | 20 | 1.010 |
Why?
|
| Patient Care | 2 | 2021 | 100 | 0.990 |
Why?
|
| Apolipoproteins E | 9 | 2014 | 189 | 0.960 |
Why?
|
| United States Food and Drug Administration | 4 | 2023 | 148 | 0.920 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2013 | 61 | 0.860 |
Why?
|
| Azepines | 2 | 2013 | 61 | 0.850 |
Why?
|
| Treatment Outcome | 35 | 2024 | 12119 | 0.850 |
Why?
|
| Alanine | 2 | 2013 | 180 | 0.840 |
Why?
|
| Amyloidosis | 1 | 2022 | 65 | 0.780 |
Why?
|
| Mental Status Schedule | 14 | 2016 | 44 | 0.730 |
Why?
|
| Antiparkinson Agents | 4 | 2024 | 65 | 0.720 |
Why?
|
| Positron-Emission Tomography | 8 | 2024 | 290 | 0.680 |
Why?
|
| Research | 2 | 2021 | 263 | 0.670 |
Why?
|
| Medical Futility | 1 | 2020 | 36 | 0.670 |
Why?
|
| Pseudobulbar Palsy | 2 | 2016 | 4 | 0.650 |
Why?
|
| Quinidine | 2 | 2016 | 9 | 0.650 |
Why?
|
| Dextromethorphan | 2 | 2016 | 11 | 0.650 |
Why?
|
| Geriatric Assessment | 9 | 2012 | 169 | 0.630 |
Why?
|
| Longitudinal Studies | 9 | 2017 | 1306 | 0.620 |
Why?
|
| Biomarkers | 22 | 2022 | 2943 | 0.600 |
Why?
|
| Indoles | 2 | 2009 | 180 | 0.590 |
Why?
|
| Parkinson Disease | 4 | 2024 | 676 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2025 | 3545 | 0.540 |
Why?
|
| Drug Discovery | 3 | 2017 | 170 | 0.540 |
Why?
|
| Mental Recall | 2 | 2015 | 142 | 0.530 |
Why?
|
| Markov Chains | 1 | 2016 | 83 | 0.500 |
Why?
|
| Models, Statistical | 4 | 2018 | 470 | 0.480 |
Why?
|
| tau Proteins | 8 | 2022 | 189 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2013 | 1071 | 0.460 |
Why?
|
| Oligonucleotides | 2 | 2024 | 88 | 0.440 |
Why?
|
| Intelligence Tests | 4 | 2012 | 57 | 0.420 |
Why?
|
| Vitamin E | 6 | 2010 | 64 | 0.420 |
Why?
|
| Attention | 6 | 2012 | 195 | 0.420 |
Why?
|
| Language | 9 | 2016 | 201 | 0.420 |
Why?
|
| Huntington Disease | 2 | 2024 | 141 | 0.410 |
Why?
|
| Drug Therapy, Combination | 4 | 2012 | 1139 | 0.410 |
Why?
|
| Regression Analysis | 4 | 2013 | 770 | 0.400 |
Why?
|
| Functional Laterality | 6 | 1999 | 181 | 0.400 |
Why?
|
| International Cooperation | 7 | 2022 | 157 | 0.400 |
Why?
|
| Early Diagnosis | 5 | 2018 | 179 | 0.380 |
Why?
|
| Interview, Psychological | 1 | 2012 | 99 | 0.380 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 2840 | 0.360 |
Why?
|
| Patient Dropouts | 2 | 2016 | 51 | 0.360 |
Why?
|
| Advisory Committees | 6 | 2024 | 148 | 0.350 |
Why?
|
| Caregivers | 8 | 2024 | 572 | 0.340 |
Why?
|
| Health Policy | 2 | 2009 | 213 | 0.340 |
Why?
|
| Apolipoprotein E4 | 8 | 2016 | 43 | 0.340 |
Why?
|
| Attitude to Health | 2 | 2009 | 260 | 0.340 |
Why?
|
| Multicenter Studies as Topic | 4 | 2016 | 261 | 0.330 |
Why?
|
| Memory | 8 | 2012 | 361 | 0.310 |
Why?
|
| Patient Compliance | 2 | 2009 | 466 | 0.310 |
Why?
|
| Basal Ganglia Diseases | 4 | 2000 | 27 | 0.310 |
Why?
|
| United States | 16 | 2023 | 10653 | 0.310 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 622 | 0.310 |
Why?
|
| Adult | 20 | 2024 | 29010 | 0.310 |
Why?
|
| Trust | 1 | 2009 | 75 | 0.300 |
Why?
|
| Patient Selection | 3 | 2013 | 683 | 0.300 |
Why?
|
| Algorithms | 7 | 2016 | 1598 | 0.300 |
Why?
|
| Research Design | 4 | 2021 | 676 | 0.300 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2018 | 67 | 0.290 |
Why?
|
| Insulin | 1 | 2013 | 1200 | 0.290 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 807 | 0.290 |
Why?
|
| Amyloidogenic Proteins | 3 | 2022 | 6 | 0.290 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 300 | 0.280 |
Why?
|
| Depression | 4 | 2012 | 1227 | 0.280 |
Why?
|
| Drug Industry | 4 | 2017 | 45 | 0.260 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 1997 | 105 | 0.260 |
Why?
|
| Informed Consent | 1 | 2009 | 341 | 0.260 |
Why?
|
| Asymptomatic Diseases | 2 | 2022 | 77 | 0.250 |
Why?
|
| Dementia, Vascular | 3 | 2015 | 16 | 0.250 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2016 | 29 | 0.250 |
Why?
|
| alpha-Synuclein | 2 | 2024 | 114 | 0.240 |
Why?
|
| Treatment Failure | 4 | 2014 | 335 | 0.240 |
Why?
|
| Primary Health Care | 1 | 2011 | 752 | 0.230 |
Why?
|
| Cohort Studies | 14 | 2022 | 4700 | 0.230 |
Why?
|
| Models, Psychological | 2 | 2010 | 138 | 0.230 |
Why?
|
| Phenylcarbamates | 2 | 2006 | 15 | 0.230 |
Why?
|
| Psychotic Disorders | 2 | 1995 | 140 | 0.220 |
Why?
|
| Observer Variation | 5 | 2011 | 300 | 0.220 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 126 | 0.220 |
Why?
|
| Likelihood Functions | 3 | 2012 | 112 | 0.220 |
Why?
|
| Nerve Degeneration | 2 | 1996 | 125 | 0.210 |
Why?
|
| Aphasia | 2 | 1993 | 14 | 0.210 |
Why?
|
| Medical History Taking | 1 | 2003 | 105 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2009 | 516 | 0.210 |
Why?
|
| China | 3 | 2021 | 241 | 0.210 |
Why?
|
| Age of Onset | 6 | 2014 | 581 | 0.210 |
Why?
|
| Geriatrics | 1 | 2003 | 72 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 2 | 1997 | 434 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 1681 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2021 | 6028 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 1008 | 0.210 |
Why?
|
| Alleles | 2 | 2005 | 1603 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 713 | 0.200 |
Why?
|
| Case-Control Studies | 10 | 2019 | 3235 | 0.200 |
Why?
|
| Computer Communication Networks | 1 | 2022 | 15 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 528 | 0.200 |
Why?
|
| Education | 4 | 2009 | 105 | 0.200 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 228 | 0.190 |
Why?
|
| Time Factors | 7 | 2017 | 6221 | 0.190 |
Why?
|
| Tacrine | 1 | 2001 | 2 | 0.190 |
Why?
|
| Visual Perception | 2 | 2004 | 124 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 1305 | 0.190 |
Why?
|
| Lipids | 3 | 2019 | 514 | 0.190 |
Why?
|
| Risk Factors | 10 | 2020 | 10022 | 0.190 |
Why?
|
| Factor Analysis, Statistical | 3 | 2012 | 229 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 3076 | 0.180 |
Why?
|
| Self-Assessment | 3 | 2006 | 66 | 0.180 |
Why?
|
| Psychomotor Performance | 3 | 2012 | 182 | 0.180 |
Why?
|
| Diarrhea | 2 | 2015 | 315 | 0.180 |
Why?
|
| Genotype | 7 | 2017 | 2533 | 0.180 |
Why?
|
| Sensitivity and Specificity | 7 | 2011 | 2011 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 70 | 0.170 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 3371 | 0.170 |
Why?
|
| Prevalence | 5 | 2016 | 2395 | 0.170 |
Why?
|
| Motor Activity | 3 | 2004 | 521 | 0.170 |
Why?
|
| Analysis of Variance | 3 | 2011 | 1009 | 0.170 |
Why?
|
| Extremities | 1 | 2000 | 83 | 0.160 |
Why?
|
| Social Behavior | 3 | 2012 | 207 | 0.160 |
Why?
|
| Awareness | 4 | 2005 | 81 | 0.160 |
Why?
|
| DNA Copy Number Variations | 3 | 2014 | 940 | 0.160 |
Why?
|
| Microglia | 2 | 2017 | 96 | 0.160 |
Why?
|
| Heptanoic Acids | 2 | 2010 | 77 | 0.160 |
Why?
|
| Diagnosis, Differential | 5 | 2011 | 1876 | 0.150 |
Why?
|
| Thiadiazines | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cyclic S-Oxides | 1 | 2018 | 2 | 0.150 |
Why?
|
| Drug Combinations | 2 | 2016 | 269 | 0.150 |
Why?
|
| Mental Processes | 3 | 2009 | 41 | 0.150 |
Why?
|
| Immunity | 1 | 2019 | 180 | 0.150 |
Why?
|
| Aggression | 2 | 2010 | 225 | 0.150 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 17 | 0.140 |
Why?
|
| Verbal Behavior | 1 | 1997 | 52 | 0.140 |
Why?
|
| Pyrroles | 2 | 2010 | 178 | 0.140 |
Why?
|
| Elder Abuse | 2 | 2008 | 24 | 0.140 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 2113 | 0.140 |
Why?
|
| Genetic Loci | 1 | 2019 | 332 | 0.140 |
Why?
|
| Lewy Body Disease | 2 | 2015 | 18 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2003 | 1325 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 17 | 0.140 |
Why?
|
| Movement Disorders | 1 | 2000 | 221 | 0.140 |
Why?
|
| Cerebral Cortex | 2 | 2000 | 448 | 0.140 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 109 | 0.140 |
Why?
|
| Statistics as Topic | 2 | 2016 | 250 | 0.140 |
Why?
|
| Acetamides | 1 | 2017 | 46 | 0.130 |
Why?
|
| Data Accuracy | 1 | 2016 | 25 | 0.130 |
Why?
|
| Self Concept | 3 | 2005 | 157 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 593 | 0.130 |
Why?
|
| Frontotemporal Dementia | 1 | 2015 | 40 | 0.120 |
Why?
|
| Nervous System | 1 | 1996 | 128 | 0.120 |
Why?
|
| Antipsychotic Agents | 2 | 2017 | 375 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 411 | 0.120 |
Why?
|
| Headache | 1 | 2015 | 108 | 0.120 |
Why?
|
| Judgment | 2 | 2012 | 35 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 93 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2017 | 372 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 5039 | 0.110 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 56 | 0.110 |
Why?
|
| Korea | 2 | 2011 | 35 | 0.110 |
Why?
|
| Gene Dosage | 2 | 2013 | 440 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2014 | 117 | 0.110 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2014 | 57 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 227 | 0.110 |
Why?
|
| Spasm | 2 | 2009 | 48 | 0.110 |
Why?
|
| Placebos | 3 | 2021 | 238 | 0.110 |
Why?
|
| Endpoint Determination | 2 | 2013 | 53 | 0.110 |
Why?
|
| Receptors, Complement 3b | 1 | 2013 | 8 | 0.110 |
Why?
|
| Apathy | 1 | 2012 | 9 | 0.100 |
Why?
|
| Neuropsychology | 1 | 2013 | 23 | 0.100 |
Why?
|
| Mental Health | 1 | 1996 | 347 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 2587 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 2012 | 28 | 0.100 |
Why?
|
| Brain Damage, Chronic | 1 | 1992 | 30 | 0.100 |
Why?
|
| Aging | 4 | 2011 | 1176 | 0.100 |
Why?
|
| Dominance, Cerebral | 1 | 1992 | 54 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 1992 | 46 | 0.100 |
Why?
|
| Fetal Hypoxia | 1 | 2012 | 13 | 0.100 |
Why?
|
| Antioxidants | 3 | 2009 | 338 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 1638 | 0.100 |
Why?
|
| Binomial Distribution | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 110 | 0.100 |
Why?
|
| Biostatistics | 1 | 2012 | 10 | 0.100 |
Why?
|
| Hobbies | 1 | 2012 | 4 | 0.100 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 20 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 1863 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 62 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 1992 | 195 | 0.100 |
Why?
|
| Executive Function | 1 | 2012 | 105 | 0.100 |
Why?
|
| Memory Disorders | 2 | 2012 | 235 | 0.100 |
Why?
|
| Linear Models | 4 | 2013 | 669 | 0.100 |
Why?
|
| Diagnostic Imaging | 3 | 2012 | 270 | 0.100 |
Why?
|
| Orientation | 1 | 2012 | 49 | 0.100 |
Why?
|
| Hand | 1 | 1992 | 101 | 0.100 |
Why?
|
| Movement | 2 | 2008 | 170 | 0.100 |
Why?
|
| Problem Solving | 1 | 2012 | 63 | 0.100 |
Why?
|
| Serum | 1 | 2011 | 46 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 99 | 0.100 |
Why?
|
| Social Adjustment | 1 | 2012 | 85 | 0.100 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 120 | 0.100 |
Why?
|
| Bias | 1 | 2012 | 124 | 0.090 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 294 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 153 | 0.090 |
Why?
|
| Plasma | 1 | 2011 | 96 | 0.090 |
Why?
|
| Lithium Chloride | 1 | 2011 | 8 | 0.090 |
Why?
|
| Sphingomyelins | 1 | 2011 | 16 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 848 | 0.090 |
Why?
|
| Palate, Soft | 1 | 1990 | 16 | 0.090 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2011 | 29 | 0.090 |
Why?
|
| Voice Disorders | 1 | 1990 | 18 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2012 | 280 | 0.090 |
Why?
|
| Intelligence | 2 | 2013 | 98 | 0.090 |
Why?
|
| Myoclonus | 1 | 1990 | 32 | 0.090 |
Why?
|
| Texas | 5 | 2011 | 3565 | 0.090 |
Why?
|
| Publishing | 1 | 2011 | 108 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2023 | 16050 | 0.090 |
Why?
|
| Sex Factors | 2 | 2004 | 1261 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2010 | 116 | 0.090 |
Why?
|
| Quality of Health Care | 2 | 2006 | 391 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 467 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2011 | 169 | 0.080 |
Why?
|
| Hippocampus | 3 | 2017 | 819 | 0.080 |
Why?
|
| Psychomotor Agitation | 1 | 2010 | 56 | 0.080 |
Why?
|
| Histamine Antagonists | 1 | 2009 | 17 | 0.080 |
Why?
|
| Weight Loss | 1 | 2013 | 479 | 0.080 |
Why?
|
| Nausea | 1 | 2009 | 97 | 0.080 |
Why?
|
| Government Agencies | 1 | 2009 | 11 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 3 | 1998 | 60 | 0.080 |
Why?
|
| Health Services Administration | 1 | 2009 | 11 | 0.080 |
Why?
|
| Drug and Narcotic Control | 1 | 2009 | 18 | 0.080 |
Why?
|
| Survival | 2 | 2006 | 19 | 0.080 |
Why?
|
| National Health Programs | 1 | 2009 | 19 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2012 | 630 | 0.080 |
Why?
|
| Public Policy | 1 | 2009 | 51 | 0.080 |
Why?
|
| Russia | 1 | 2008 | 39 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 86 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2009 | 94 | 0.080 |
Why?
|
| Europe | 2 | 2010 | 350 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2011 | 1172 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1290 | 0.070 |
Why?
|
| Educational Status | 2 | 2011 | 270 | 0.070 |
Why?
|
| Motor Skills | 1 | 2008 | 83 | 0.070 |
Why?
|
| Reaction Time | 2 | 2005 | 170 | 0.070 |
Why?
|
| Galantamine | 2 | 2006 | 10 | 0.070 |
Why?
|
| Cost of Illness | 2 | 2010 | 242 | 0.070 |
Why?
|
| Rivastigmine | 2 | 2006 | 17 | 0.070 |
Why?
|
| Primary Prevention | 2 | 2006 | 164 | 0.070 |
Why?
|
| Proxy | 1 | 2006 | 15 | 0.070 |
Why?
|
| Technetium Tc 99m Exametazime | 2 | 1997 | 8 | 0.070 |
Why?
|
| Organotechnetium Compounds | 2 | 1997 | 12 | 0.070 |
Why?
|
| Speech | 2 | 2000 | 57 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 1268 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2008 | 1389 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 796 | 0.070 |
Why?
|
| Oximes | 2 | 1997 | 48 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 586 | 0.070 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 15 | 0.060 |
Why?
|
| Mass Screening | 1 | 2011 | 786 | 0.060 |
Why?
|
| Delusions | 2 | 1995 | 17 | 0.060 |
Why?
|
| Mental Competency | 1 | 2006 | 51 | 0.060 |
Why?
|
| Managed Care Programs | 1 | 2006 | 61 | 0.060 |
Why?
|
| ROC Curve | 3 | 2017 | 558 | 0.060 |
Why?
|
| Hallucinations | 2 | 1995 | 26 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 230 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1479 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2005 | 24 | 0.060 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2024 | 12 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2007 | 437 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2003 | 365 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 150 | 0.060 |
Why?
|
| Incidence | 5 | 2010 | 3039 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2011 | 314 | 0.060 |
Why?
|
| Levodopa | 1 | 2024 | 90 | 0.060 |
Why?
|
| Monoamine Oxidase | 1 | 2024 | 11 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 229 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 143 | 0.060 |
Why?
|
| Self Care | 1 | 2006 | 213 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2019 | 151 | 0.060 |
Why?
|
| Consensus | 2 | 2022 | 607 | 0.060 |
Why?
|
| Anthropometry | 1 | 2004 | 197 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 4284 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1679 | 0.060 |
Why?
|
| Linguistics | 2 | 1993 | 18 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2004 | 140 | 0.050 |
Why?
|
| N-Methylaspartate | 1 | 2003 | 29 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 697 | 0.050 |
Why?
|
| Neuroimaging | 2 | 2018 | 332 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 74 | 0.050 |
Why?
|
| Comorbidity | 3 | 2002 | 1497 | 0.050 |
Why?
|
| Patients | 1 | 2024 | 121 | 0.050 |
Why?
|
| Behavioral Symptoms | 1 | 2003 | 25 | 0.050 |
Why?
|
| History, 19th Century | 2 | 1993 | 115 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 720 | 0.050 |
Why?
|
| Carbamates | 1 | 2003 | 58 | 0.050 |
Why?
|
| Tremor | 1 | 2024 | 129 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2003 | 95 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 34 | 0.050 |
Why?
|
| Amyloid | 1 | 2022 | 65 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2008 | 957 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 336 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2002 | 57 | 0.050 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 3666 | 0.050 |
Why?
|
| Smoking | 2 | 2004 | 1030 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 84 | 0.050 |
Why?
|
| History, 20th Century | 2 | 1993 | 381 | 0.050 |
Why?
|
| Brain Edema | 2 | 2013 | 69 | 0.050 |
Why?
|
| Prosopagnosia | 1 | 2001 | 1 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2021 | 6 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 862 | 0.050 |
Why?
|
| Learning | 1 | 2004 | 361 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 329 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 5 | 1998 | 1258 | 0.040 |
Why?
|
| Quality of Life | 2 | 2001 | 1923 | 0.040 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2000 | 16 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2012 | 397 | 0.040 |
Why?
|
| Atrophy | 2 | 2013 | 226 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2000 | 44 | 0.040 |
Why?
|
| Prognosis | 2 | 2016 | 4512 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 2019 | 28 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 1999 | 40 | 0.040 |
Why?
|
| Hypertension | 2 | 2004 | 1286 | 0.040 |
Why?
|
| Age Factors | 1 | 2004 | 2799 | 0.040 |
Why?
|
| Drug Design | 2 | 2009 | 146 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 517 | 0.040 |
Why?
|
| European Union | 1 | 2017 | 13 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2017 | 76 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 1 | 2000 | 253 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 1999 | 348 | 0.030 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 399 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 309 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 657 | 0.030 |
Why?
|
| Dysarthria | 1 | 1996 | 21 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 349 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 1997 | 116 | 0.030 |
Why?
|
| Spain | 1 | 2016 | 53 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 2394 | 0.030 |
Why?
|
| Perfusion | 1 | 1997 | 198 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 715 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 1995 | 42 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1995 | 110 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 1473 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1243 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2014 | 86 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 123 | 0.030 |
Why?
|
| Speech-Language Pathology | 1 | 1993 | 13 | 0.030 |
Why?
|
| Language Disorders | 1 | 1993 | 24 | 0.030 |
Why?
|
| Stroke | 2 | 2016 | 955 | 0.030 |
Why?
|
| Thailand | 1 | 2013 | 34 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 1413 | 0.030 |
Why?
|
| History, 18th Century | 1 | 1993 | 69 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 2013 | 122 | 0.030 |
Why?
|
| Speech Disorders | 1 | 1993 | 42 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1996 | 299 | 0.030 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 37 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 2695 | 0.030 |
Why?
|
| Registries | 3 | 2009 | 1394 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 75 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 996 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 1040 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1995 | 378 | 0.030 |
Why?
|
| Family | 1 | 1995 | 571 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 1992 | 98 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 517 | 0.020 |
Why?
|
| Aphasia, Broca | 1 | 1991 | 1 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 518 | 0.020 |
Why?
|
| Emotions | 2 | 2005 | 361 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 120 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2011 | 93 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 268 | 0.020 |
Why?
|
| Decision Making | 1 | 1996 | 651 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2012 | 217 | 0.020 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 371 | 0.020 |
Why?
|
| Receptors, Odorant | 1 | 2011 | 36 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 64 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 100 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 268 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1012 | 0.020 |
Why?
|
| Visual Cortex | 1 | 2012 | 109 | 0.020 |
Why?
|
| Triglycerides | 1 | 2013 | 561 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 760 | 0.020 |
Why?
|
| Community Mental Health Services | 1 | 2010 | 38 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 51 | 0.020 |
Why?
|
| Astrocytes | 1 | 2012 | 250 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 544 | 0.020 |
Why?
|
| Family Relations | 1 | 2010 | 69 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 792 | 0.020 |
Why?
|
| Social Environment | 1 | 2010 | 120 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 72 | 0.020 |
Why?
|
| Federal Government | 1 | 2009 | 15 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 573 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2010 | 95 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 412 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 424 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 760 | 0.020 |
Why?
|
| Reference Standards | 2 | 2002 | 239 | 0.020 |
Why?
|
| Synapses | 1 | 2012 | 449 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1610 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 697 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2009 | 83 | 0.020 |
Why?
|
| Handwriting | 1 | 2008 | 8 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2011 | 1081 | 0.020 |
Why?
|
| Mental Disorders | 2 | 2013 | 826 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 134 | 0.020 |
Why?
|
| Models, Biological | 1 | 1993 | 1442 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 354 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 816 | 0.020 |
Why?
|
| Heterozygote | 1 | 2009 | 678 | 0.020 |
Why?
|
| Computational Biology | 1 | 2011 | 804 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 469 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2010 | 451 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 557 | 0.020 |
Why?
|
| Hygiene | 1 | 2006 | 24 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1797 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1112 | 0.020 |
Why?
|
| Demography | 1 | 2005 | 239 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 17538 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 234 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2005 | 190 | 0.010 |
Why?
|
| Genomics | 1 | 2012 | 1474 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 500 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4226 | 0.010 |
Why?
|
| Behavior | 1 | 2003 | 75 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 715 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 450 | 0.010 |
Why?
|
| Medicare | 1 | 2006 | 424 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 226 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 2000 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3327 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 33793 | 0.010 |
Why?
|
| Neurology | 1 | 2002 | 107 | 0.010 |
Why?
|
| Pregnancy | 1 | 2012 | 7138 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 381 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 482 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2000 | 185 | 0.010 |
Why?
|
| Local Government | 1 | 1997 | 3 | 0.010 |
Why?
|
| Retirement | 1 | 1997 | 18 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1997 | 108 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 19094 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1992 | 21 | 0.010 |
Why?
|
| Writing | 1 | 1992 | 63 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 2055 | 0.000 |
Why?
|